¼¼°èÀÇ ÁÖ»ç¿ë ¼¼Æ÷ µ¶¼º ¾à¹° ½ÃÀå ¿¹Ãø(-2030³â) : ºÎ¹®º° ºÐ¼®
Injectable Cytotoxic Drugs Market Forecasts to 2030 - Global Analysis By Drug Type, Distribution Channel, Application, and By Geography
»óǰÄÚµå : 1453996
¸®¼­Ä¡»ç : Stratistics Market Research Consulting
¹ßÇàÀÏ : 2024³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200+ Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,150 £Ü 6,004,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,596,000
PDF (2-5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ±îÁö °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,350 £Ü 9,187,000
PDF & Excel (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ±îÁö °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,500 £Ü 10,851,000
PDF & Excel (Global Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 10ȸ±îÁö °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÁÖ»ç¿ë ¼¼Æ÷ µ¶¼º ¾à¹°(Injectable Cytotoxic Drugs) ½ÃÀåÀº 2023³â¿¡ 189¾ï ´Þ·¯¿´À¸¸ç, ¿¹Ãø ±â°£ µ¿¾È CAGR 7.4%·Î ÃßÀÌÇÏ¸ç ¼ºÀå ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2030³â¿¡´Â 311¾ï ´Þ·¯¿¡ À̸¦ Àü¸ÁÀÔ´Ï´Ù.

ÁÖ»ç¿ë ¼¼Æ÷ µ¶¼º ¾à¹°À̶õ, ºü¸£°Ô ºÐ¿­ÇÏ´Â ¾Ï¼¼Æ÷¸¦ Ç¥ÀûÀ¸·Î »ï¾Æ ÆÄ±«ÇÔÀ¸·Î½á ´Ù¾çÇÑ ¾ÏÀ» Ä¡·áÇϱâ À§ÇØ Áֻ縦 ÅëÇØ Åõ¿©ÇÏ´Â ¾à¹°À» ¸»ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¾à¹°Àº ¼¼Æ÷ ºÐ¿­ °úÁ¤À» ¹æÇØÇϰųª ¼¼Æ÷ »ç¸êÀ» À¯µµÇϰųª Á¾¾ç ¼ºÀåÀ» ¾ïÁ¦ÇÏ´Â ¹æ½ÄÀ¸·Î ÀÛ¿ëÇÕ´Ï´Ù. È­ÇÐ ¿ä¹ý¿¡ ÀÚÁÖ »ç¿ëµÇ´Â ¸ÞÅ䯮·º¼¼ÀÌÆ®, µ¶¼Ò·çºñ½Å, ºóÅ©¸®½ºÆ¾°ú °°Àº ¾àÁ¦°¡ ¿©±â¿¡ Æ÷ÇԵ˴ϴÙ. ºÎÀÛ¿ë¿¡µµ ºÒ±¸Çϰí ÁÖ»ç¿ë ¼¼Æ÷µ¶¼º ¾à¹°Àº Á¾¾çÀ» Ãà¼ÒÇϰí ÀüÀ̸¦ ¹æÁöÇϸç ȯÀÚÀÇ Àü¹ÝÀûÀÎ »ýÁ¸À²À» °³¼±Çϱâ À§ÇØ ´Üµ¶À¸·Î ¶Ç´Â ´Ù¸¥ Ä¡·á¹ý°ú ÇÔ²² »ç¿ëµÇ´Â °æ¿ì°¡ ¸¹¾Æ ¾Ï Ä¡·á¿¡¼­ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

°Ç°­ °ü¸® ÁöÃâ Áõ°¡

ÇコÄɾîÀÇ ¿¹»êÀÌ È®´ëµÊ¿¡ µû¶ó Áֻ翡 ÀÇÇÑ ¼¼Æ÷µ¶¼º¾àÀ» Æ÷ÇÔÇÑ ¼±ÁøÀûÀÎ ¾Ï Ä¡·á¿¡ ´ëÇÑ Á¢±Ùµµ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ÁöÃâ Áõ°¡·Î °Ç°­ °ü¸® ½Ã½ºÅÛÀº ¾ÏÀ¸·Î Áø´Ü¹ÞÀº ȯÀÚ¿¡°Ô ´Ù¾çÇÑ Ä¡·á ¿É¼ÇÀ» Á¶´ÞÇϰí Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á½Ã¼³Àº ÁÖ»ç¿ë ¼¼Æ÷ µ¶¼º ¾àÁ¦ÀÇ º¸°ü, Åõ¿©, °ü¸®¿¡ ´ëÀÀÇϱâ À§ÇÑ ¼³ºñ°¡ °®Ãß¾îÁ® ÀÖ¾î, ¾Ï Ä¡·á ¿ä¹ý¿¡¼­ »ç¿ëÀÌ ´õ¿í ¿ëÀÌÇØÁ®, ÀÌ ½ÃÀåÀ» ÇÑÃþ ´õ ÃßÁøÇϰí ÀÖ½À´Ï´Ù.

³ôÀº °³¹ß ºñ¿ë

»õ·Î¿î ¼¼Æ÷ µ¶¼º ¾à¹°ÀÇ °³¹ß¿¡´Â ´ë±Ô¸ð ÀüÀÓ»ó½ÃÇè, ÀÓ»ó½ÃÇè ¹× ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀÌ ÇÊ¿äÇÏ¸ç °øÁ¤ÀÇ °¢ ´Ü°è¿¡¼­ ¸¹Àº ºñ¿ëÀÌ ¹ß»ýÇϱ⠶§¹®¿¡ Á¦¾à ±â¾÷¿¡°Ô´Â Å« À繫Àû ºÎ´ãÀ̵˴ϴÙ. ¶ÇÇÑ ¹Ì±¹ÀÇ FDA¿Í À¯·´ÀÇ EMA¿Í °°Àº ±ÔÁ¦ ´ç±¹À¸·ÎºÎÅÍÀÇ ½ÂÀÎ ÃëµæÀ̳ª ±ÔÁ¦ ¿ä°Ç¿¡ ´ëÇÑ ´ëÀÀÀÌ °³¹ß ºñ¿ë¿¡ ¹ÚÂ÷¸¦ °¡ÇØ ½ÃÀå °³Ã´ÀÇ ¹ßÆÇÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ÀǾàǰ °³¹ßÀÇ Áøº¸

¾à¹° Á¦Á¶ ±â¼ú Áøº¸·Î ¾à¹° Àü´Þ ¹× Á¶Á÷ ħÅõ¸¦ °³¼±ÇÏ´Â º¸´Ù ¾ÈÁ¤ÀûÀÌ°í »ý¹°ÇÐÀû À̿밡´ÉÇÑ ¼¼Æ÷µ¶¼º ¾à¹° Á¦Á¦°¡ °³¹ßµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ Áøº¸´Â â¾à, Á¦ÇüÈ­ ¹× Àü´ÞÀÇ ´Ù¾çÇÑ Ãø¸éÀ» Æ÷ÇÔÇÏ¿© ´õ¿í ¾ÈÀüÇϰí È¿°úÀûÀÎ ¼¼Æ÷ µ¶¼º ¿ä¹ýÀÇ °³¹ß¿¡ ±â¿©ÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ Á¢±Ù¹ýÀ» ÅëÇØ ¿¬±¸ÀÚµéÀº ¾Ï¼¼Æ÷¿¡ ´ëÇÑ ¼±Åüº°ú È¿´ÉÀÌ °­È­µÈ È­ÇÕ¹°À» È®ÀÎÇÒ ¼ö ÀÖ°Ô µÇ´Â µ¿½Ã¿¡ Ç¥Àû ¹Û¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ°Ô µÇ¾î ÀÌ ½ÃÀå ´õ ÃßÁøÇϰí ÀÖ½À´Ï´Ù.

ºÎÀÛ¿ë°ú µ¶¼º

ÀÌ·¯ÇÑ ¾àÁ¦´Â ±Þ¼ÓÇÏ°Ô ºÐ¿­ÇÏ´Â ¾Ï¼¼Æ÷¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â Á¡¿¡¼­´Â È¿°úÀûÀÌÁö¸¸, ȯÀÚÀÇ QOLÀ̳ª Ä¡·áÀÇ ¾îµåÈ÷¾î·±½º¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ºÎÀÛ¿ëÀ» ÀÏÀ¸Å°´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÁÖ»ç¿ë ¼¼Æ÷µ¶¼º ¾à¹°ÀÇ ÀϹÝÀûÀÎ ºÎÀÛ¿ëÀ¸·Î´Â ¸Þ½º²¨¿ò, ±¸Åä, Å»¸ð, ÇÇ·Î, ¸é¿ª¾ïÁ¦ µîÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ È¯ÀÚ´Â ÀÌÂ÷ ¾ÏÀ̳ª Àå±â Àå¾Ö¿Í °°Àº ¼¼Æ÷µ¶¼º ¾à¹°¿¡ ³ëÃâµÇ¾î Àå±âÀûÀÎ ÇÕº´ÁõÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¸ç, ÀÌ´Â ÀÌ ½ÃÀå ±Ô¸ðÀÇ ¹æÇذ¡ µÇ°í ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇâ

COVID-19 ÆÒµ¥¹ÍÀº ÁÖ»ç¿ë ¼¼Æ÷µ¶¼º ¾à¹° ½ÃÀå¿¡ ¸î °¡Áö ¾Ç¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ¼¼°èÀÇ °Ç°­ °ü¸® ½Ã½ºÅÛÀÇ È¥¶õÀº ¾Ï °ËÁø, Áø´Ü, Ä¡·á Áö¿¬À¸·Î À̾îÁ® ȯÀÚ ¼öÀÇ °¨¼Ò¸¦ °¡Á®¿Ô½À´Ï´Ù. ¶ÇÇÑ, ºÀ¼â, ¿©Çà Á¦ÇÑ, °ø±Þ¸Á È¥¶õÀ¸·Î ÀÎÇÑ ¹°·ù ¹®Á¦´Â ÁÖ»ç¿ë ¼¼Æ÷ µ¶¼º ¾à¹°ÀÇ »ý»ê, À¯Åë ¹× Àü´ÞÀ» ¹æÇØÇÕ´Ï´Ù. À̰ÍÀº ƯÈ÷ ÀÚ¿øÀÌ Á¦ÇÑµÈ È¯°æ¿¡¼­ ÁÖ»ç¿ë ¼¼Æ÷µ¶¼º ¾à¹°¿¡ ´ëÇÑ È¯ÀÚÀÇ Á¢±Ù¿¡ ´õ¿í ¿µÇâÀ» ¹ÌÄ¡°í, ÀÌ ½ÃÀåÀ» ÇöÀúÇÏ°Ô ÀúÇØÇϰí ÀÖ½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È ºóÄ« ¾ËÄ®·ÎÀÌµå ºÎ¹®ÀÌ ÃÖ´ë°¡ µÉ Àü¸Á

ºóÄ« ¾ËÄ®·ÎÀÌµå ºÎ¹®Àº ¾Ï Ä¡·á¿¡¼­ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒ ¶§¹®¿¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ÀÌ ¾àÀº ¹Ì¼¼ ¼Ò°ü Çü¼ºÀ» ¾ïÁ¦ÇÔÀ¸·Î½á ¼¼Æ÷ ºÐ¿­À» ¾ïÁ¦ÇÏ°í ºü¸£°Ô ºÐ¿­ÇÏ´Â ¾Ï¼¼Æ÷¿¡ ¾ÆÆüÅä½Ã½º¸¦ À¯µµÇÕ´Ï´Ù. ¶ÇÇÑ, ÇöÀç ÁøÇà ÁßÀÎ R&D´Â ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϸ鼭 ºóÄ« ¾ËÄ®·ÎÀ̵åÀÇ Ä¡·á È¿°ú¸¦ ÃÖÀûÈ­ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϸç, À̷νá ÀÌ ºÎ¹®ÀÇ È®´ë¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

´Ù¹ß¼º °æÈ­Áõ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀÌ ¿¹»ó

´Ù¹ß¼º °æÈ­Áõ ºÎ¹®Àº ÇöÀúÇÑ ¼ºÀå°ú Çõ½ÅÀ¸·Î ¿¹Ãø ±â°£ µ¿¾È CAGRÀÌ °¡Àå ³ôÀ» °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÎÅÍÆä·Ð ¥â1a ¾à¹°°ú ÀÎÅÍÆä·Ð ¥â1b ¾à¹°Àº ¸é¿ª°èÀÇ ¹ÝÀÀÀ» Á¶ÀýÇϰí MS ȯÀÚÀÇ ¿°Áõ°ú Àç¹ß ºóµµ¸¦ ÁÙÀÌ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ, ƯÁ¤ ¸é¿ª°æ·Î¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â ´ÜŬ·ÐÇ×ü¿Í °°Àº »õ·Î¿î Ä¡·áÁ¦°¡ MS ȯÀÚÀÇ Ä¡·á ¿É¼ÇÀ» ³ÐÈ÷°í ÀÖÀ¸¸ç, ÀÌ ºÐ¾ß ¼ºÀåÀ» À̲ø°í ÀÖ½À´Ï´Ù.

ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª

ºÏ¹Ì´Â ¾ÏÀ̳ª ´Ù¹ß¼º °æÈ­Áõ µî ÀÚ°¡¸é¿ªÁúȯÀÇ À¯º´·üÀÌ ³ô±â ¶§¹®¿¡ ÀÌ Áö¿ª Àüü¿¡¼­ ÁÖ»ç¿ë ¼¼Æ÷ µ¶¼º ¾à¹°¿¡ ´ëÇÑ Å« ¼ö¿ä°¡ ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº Á¤ºñµÈ °Ç°­ °ü¸® ÀÎÇÁ¶ó, °í±Þ ÀÇ·á ½Ã¼³ ¹× ³ôÀº ¼öÁØÀÇ ÀÇ·á ÁöÃâÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À¯¸®ÇÑ »óȯ Á¤Ã¥°ú º¸Çè Àû¿ëÀº ȯÀÚµéÀÌ ÀÌ·¯ÇÑ Çʼö ÀǾàǰÀ» ¾ò´Âµ¥ ±â¿©Çϰí ÀÖÀ¸¸ç, ÀÌ Áö¿ªÀÇ È®´ë¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª :

À¯·´Àº °­·ÂÇÑ Á¦¾à »ê¾÷, ÃÖ÷´Ü ¿¬±¸, °ß°íÇÑ °Ç°­ °ü¸® ÀÎÇÁ¶ó¸¦ º¸À¯Çϰí Àֱ⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â Çмú°è, »ê¾÷°è, ±ÔÁ¦ ´ç±¹ÀÇ Çù·Â üÁ¦°¡ Çõ½ÅÀ» ÃËÁøÇÏ°í ¿¬±¸ ¼º°úÀÇ ÀÓ»ó ÀÀ¿ëÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ À¯·´¿¡¼­´Â »õ·Î¿î ¾à¹° Àü´Þ ±â¼úÀÌ Ã¤ÅõǾî ÁÖ»ç¿ë ¼¼Æ÷ µ¶¼º ¾à¹°ÀÇ Ä¡·á È¿°ú¿Í ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀÌ Çâ»óµÇ¾úÀ¸¸ç, ÀÌ´Â ÀÌ Áö¿ªÀ» ´õ¿í °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

¹«·á »ç¿ëÀÚ ÁöÁ¤ ¿ÀÆÛ¸µ :

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½ ¹«·á ¸ÂÃã¼³Á¤ ¿É¼Ç Áß Çϳª¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

Á¦4Àå Porter's Five Forces ºÐ¼®

Á¦5Àå ¼¼°èÀÇ ÁÖ»ç¿ë ¼¼Æ÷ µ¶¼º ¾à¹° ½ÃÀå : ¾àÁ¦ À¯Çüº°

Á¦6Àå ¼¼°èÀÇ ÁÖ»ç¿ë ¼¼Æ÷ µ¶¼º ¾à¹° ½ÃÀå : À¯Åë ä³Îº°

Á¦7Àå ¼¼°èÀÇ ÁÖ»ç¿ë ¼¼Æ÷ µ¶¼º ¾à¹° ½ÃÀå : ¿ëµµº°

Á¦8Àå ¼¼°èÀÇ ÁÖ»ç¿ë ¼¼Æ÷ µ¶¼º ¾à¹° ½ÃÀå : Áö¿ªº°

Á¦9Àå ÁÖ¿ä ¹ßÀü

Á¦10Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

LYJ
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

According to Stratistics MRC, the Global Injectable Cytotoxic Drugs Market is accounted for $18.9 billion in 2023 and is expected to reach $31.1 billion by 2030 growing at a CAGR of 7.4% during the forecast period. Injectable cytotoxic drugs refer to medications administered via injection to treat various cancers by targeting and destroying rapidly dividing cancer cells. These drugs work by interfering with cell division processes, inducing cell death, or inhibiting tumor growth. Often used in chemotherapy regimens, they include agents like methotrexate, doxorubicin, and vincristine. Despite their side effects, injectable cytotoxic drugs are crucial in cancer treatment, often used alone or in combination with other therapies to shrink tumors, prevent metastasis, and improve patients' overall survival rates.

Market Dynamics:

Driver:

Increasing healthcare expenditure

As healthcare budgets expand, there's greater accessibility to advanced cancer treatments, including cytotoxic drugs administered via injection. This increased spending enables healthcare systems to procure and offer a wider range of treatment options to patients diagnosed with cancer. Moreover, healthcare facilities are better equipped to handle the storage, administration, and management of injectable cytotoxic drugs, further facilitating their use in cancer treatment regimens and propelling this market further.

Restraint:

High development costs

Developing a new cytotoxic drug involves extensive preclinical studies, clinical trials, and regulatory approvals, which incur significant expenses at each stage of the process and contribute to substantial financial burdens for pharmaceutical companies. Moreover, navigating regulatory requirements and obtaining approvals from regulatory agencies such as the FDA in the United States and the EMA in Europe adds to the development costs, thereby gradually impedes this market growth.

Opportunity:

Advancements in drug development

Advancements in drug formulation technologies have led to the development of more stable, bioavailable cytotoxic drug formulations that improve drug delivery and tissue penetration. These advancements encompass various aspects of drug discovery, formulation, and delivery, contributing to the development of safer, more efficacious cytotoxic therapies. Moreover, these approaches enable researchers to identify compounds with enhanced selectivity and potency against cancer cells while minimizing off-target effects, propelling this market further.

Threat:

Side effects and toxicity

These medications, while effective in targeting rapidly dividing cancer cells, often lead to adverse effects that impact patients' quality of life and treatment adherence. Common side effects of injectable cytotoxic drugs include nausea, vomiting, hair loss, fatigue, and immunosuppression. Moreover, patients may also develop long-term complications from cytotoxic drug exposure, including secondary cancers and organ damage, which hinder this market size.

Covid-19 Impact

The COVID-19 pandemic has had several negative impacts on the injectable cytotoxic drug market. Disruptions in healthcare systems worldwide have led to delays in cancer screenings, diagnoses, and treatments, resulting in a reduction in the number of patients. Furthermore, logistical challenges arising from lockdowns, travel restrictions, and supply chain disruptions have hampered the production, distribution, and delivery of injectable cytotoxic drugs. This has further impacted patient access to injectable cytotoxic drugs, particularly in resource-limited settings, which significantly hinders this market.

The vinca alkaloids segment is expected to be the largest during the forecast period

The vinca alkaloids segment is estimated to hold the largest share, due to its pivotal role in cancer treatment. These drugs work by disrupting microtubule formation, thereby inhibiting cell division and inducing apoptosis in rapidly dividing cancer cells. Additionally, ongoing research and development efforts aim at optimizing Vinca alkaloids' therapeutic benefits while minimizing adverse effects, thereby boosting this segment's expansion.

The multiple sclerosis segment is expected to have the highest CAGR during the forecast period

The multiple sclerosis segment is anticipated to have highest CAGR during the forecast period due to its significant growth and innovation. Interferon beta-1a and interferon beta-1b drugs help regulate the immune system's response, reducing inflammation and the frequency of relapses in MS patients. Moreover, emerging therapies, including monoclonal antibodies targeting specific immune pathways, are expanding treatment options for MS patients, which is driving this segment's growth.

Region with largest share:

North America commanded the largest market share during the extrapolated period, owing to the high prevalence of cancer and autoimmune diseases such as multiple sclerosis, there is a substantial demand for injectable cytotoxic drugs across the region. The region benefits from a well-established healthcare infrastructure, advanced medical facilities, and a high level of healthcare spending. Furthermore, favorable reimbursement policies and insurance coverage contribute to patients' access to these essential medications, propelling this region's expansion.

Region with highest CAGR:

Europe is expected to witness highest CAGR over the projection period, owing to the region's strong pharmaceutical industry, cutting-edge research, and robust healthcare infrastructure. Collaborative efforts between academia, industry, and regulatory agencies in Europe foster innovation and accelerate the translation of research findings into clinical practice. In addition, Europe has witnessed the adoption of novel drug delivery technologies, enhancing the therapeutic efficacy and safety profile of injectable cytotoxic drugs, which drives this region further.

Key players in the market

Some of the key players in the Injectable Cytotoxic Drugs Market include Merck & Co. Inc., Pfizer, Inc., F. Hoffmann-La Roche Ltd., Amgen, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Sanofi, Johnson and Johnson Services Inc. , Abbie Inc, Novartis AG.

Key Developments:

In February 2024, Novartis announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG, a Germany-based, global biopharmaceutical company developing innovative medicines in oncology.

In July 2023, DTx Pharma, a preclinical stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its Fatty Acid Ligand Conjugated OligoNucleotide platform, announced that it has been acquired by Novartis.

Drug Types Covered:

Distribution Channel Covered:

Applications Covered:

Regions Covered:

What our report offers:

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Table of Contents

1 Executive Summary

2 Preface

3 Market Trend Analysis

4 Porters Five Force Analysis

5 Global Injectable Cytotoxic Drugs Market, By Drug Type

6 Global Injectable Cytotoxic Drugs Market, By Distribution Channel

7 Global Injectable Cytotoxic Drugs Market, By Application

8 Global Injectable Cytotoxic Drugs Market, By Geography

9 Key Developments

10 Company Profiling

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â